Ignite Creation Date:
2024-05-06 @ 1:58 AM
Last Modification Date:
2024-10-26 @ 11:12 AM
Study NCT ID:
NCT01945021
Status:
COMPLETED
Last Update Posted:
2021-02-21
First Post:
2013-09-05
Brief Title:
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive ALK Negative Advanced NSCLC
Sponsor:
Pfizer
Organization:
Pfizer
Organization Data
Organization:
Pfizer
Class:
INDUSTRY
Study ID:
OO 12-01
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Pfizer
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| OxOnc Development LP | OTHER |